Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

445
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
445
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

330
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
330
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

958
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
958

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Translational validity of rodent diet-induced obesity models for cognitive impairment in human metabolic disease.

Anais da Academia Brasileira de Ciencias·2026
Same author

Characterization of white adipocyte heterogeneity using data-driven microscopy.

International journal of obesity (2005)·2026
Same author

Circulating sphingosine-1-phosphate depletion is associated with endothelial activation and altered brain-endothelial S1P pathway expression in ischemic stroke.

Fluids and barriers of the CNS·2026
Same author

Brainstem GLP-1 neurons modulate physiological satiation and drive sustained weight loss in obese mice.

Molecular metabolism·2026
Same author

Is Higher Antioxidant Capacity an Important Determinant of Cognitive Performance? Editorial Highlight on "Brain Glutathione Levels Associate With Cognitive Performance in Older Adults" by Lee et al.

Journal of neurochemistry·2026
Same author

Airborne particulates and brain health: The role of PM<sub>2.5</sub> in blood-brain-barrier dysfunction.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026

相关实验视频

Updated: May 5, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.1K

在高脂肪饮食引起的肥胖症中,亚素激酶2抑制剂ABC294640在雄性小鼠中没有代谢效果.

Cecilia Skoug1, Lotte Vanherle2, Lisa Teresa Porschen2

  • 1Department of Experimental Medical Science, Faculty of Medicine, Lund University, 221 84, Lund, Sweden; Wallenberg Center for Molecular Medicine, Faculty of Medicine, Lund University, 221 84, Lund, Sweden.

Life sciences
|September 6, 2025
PubMed
概括
此摘要是机器生成的。

在小鼠中,神素激酶2 (SphK2) 抑制并没有改善饮食引起的肥胖症. 与预期相反,SphK2抑制恶化了胰岛素耐受性和脂肪细胞缩,突出显示了特定环境在代谢功能障碍中的作用.

关键词:
糖尿病肥胖问题SphK2 抑制剂斯芬戈辛-1-酸盐

更多相关视频

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.1K
Isolation of Adipogenic and Fibro-Inflammatory Stromal Cell Subpopulations from Murine Intra-Abdominal Adipose Depots
06:50

Isolation of Adipogenic and Fibro-Inflammatory Stromal Cell Subpopulations from Murine Intra-Abdominal Adipose Depots

Published on: August 16, 2020

2.8K

相关实验视频

Last Updated: May 5, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.1K
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.1K
Isolation of Adipogenic and Fibro-Inflammatory Stromal Cell Subpopulations from Murine Intra-Abdominal Adipose Depots
06:50

Isolation of Adipogenic and Fibro-Inflammatory Stromal Cell Subpopulations from Murine Intra-Abdominal Adipose Depots

Published on: August 16, 2020

2.8K

科学领域:

  • 代谢研究
  • 肥胖研究
  • 脂质的生物化学

背景情况:

  • 斯芬戈辛-1-酸盐 (S1P) 和其酶斯芬戈辛激酶1/2 (SphK1/2) 涉及肥胖.
  • 在肥胖个体中观察到血S1P水平升高.
  • 在临床前模型中,基因SphK2剥离显示出对肥胖的保护作用.

研究的目的:

  • 评估药物SphK2抑制的治疗潜力.
  • 在高脂肪饮食 (HFD) 诱导的肥胖模型中研究SphK2抑制.

主要方法:

  • 给小鼠提供HFD或对照饮食 (CD) 持续9周.
  • 在7周后,SphK2抑制剂 (SphK2i) 或载体被给予HFD养的小鼠.
  • 评估了新陈代谢参数,肝硬化和脂肪细胞特征.

主要成果:

  • 在HFD养小鼠的脂肪和肝组织中SphK2的表达增加.
  • 抑制SphK2无法减少肝硬化或改善肝脏基因表达.
  • 在HFD养的小鼠中,SphK2抑制导致胰岛素耐受性恶化和脂肪细胞增大.
  • 在CD养小鼠中,SphK2抑制对全身代谢的影响很小.

结论:

  • 药理上SphK2抑制对饮食引起的肥胖没有治疗效果.
  • 组织和环境特异性对于向化酶途径至关重要.
  • 基于这些发现,不建议广泛使用SphK2抑制治疗肥胖症.